Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe: A Role for the Combined Vaccine

@article{Vesikari2007IncreasingCA,
  title={Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe: A Role for the Combined Vaccine},
  author={T. Vesikari and C. Sadzot-Delvaux and B. Rentier and A. Gershon},
  journal={The Pediatric Infectious Disease Journal},
  year={2007},
  volume={26},
  pages={632-638}
}
  • T. Vesikari, C. Sadzot-Delvaux, +1 author A. Gershon
  • Published 2007
  • Medicine
  • The Pediatric Infectious Disease Journal
    • Universal mass vaccination according to a 2-dose measles-mumps-rubella (MMR) vaccine schedule is recommended by the World Health Organization and is fundamental to the control of these important diseases. Very high coverage (first dose, ≥95%; second dose, ≥80%) is necessary to achieve and sustain high population immunity, and eventually interrupt indigenous transmission of these diseases. In 2006, the Advisory Committee on Immunization Practices issued a recommendation for 2 doses of varicella… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    48 Citations
    Highly Influential Citations
    3
    Background Citations
    16
    Methods Citations
    2
    Results Citations
    2
    48 Citations
    Citation Type

    Citation Type

    Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    • 27
    Live Attenuated Measles Mumps and Rubella Vaccines: An Over View
    • 2
    • PDF
    Vaccines for measles, mumps, rubella, and varicella in children.
    • 15
    Measles–Mumps–Rubella–Varicella Combination Vaccine (ProQuad®): A Guide to Its Use in Children in the EU
    • 2
    Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    • 30
    Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore
    • 6
    Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
    • 7
    New combination vaccines: integration into pediatric practice.
    • 3
    Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.
    • 23
    Safety and Immunogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine Coadministered With Measles-Mumps-Rubella-Varicella Vaccine in Children Aged 12 to 16 Months
    • 34

    References

    SHOWING 1-10 OF 124 REFERENCES
    Immunogenicity and Safety of Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children
    • 98
    Evaluation of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children
    • 115
    Immunogenicity and Safety of a Second Dose of Measles–Mumps–Rubella–Varicella Vaccine in Healthy Children Aged 5 to 6 Years
    • 42
    Safety and Immunogenicity of Early Vaccination with Two Doses of Tetravalent Measles-Mumps-Rubella-Varicella (MMRV) Vaccine in Healthy Children from 9 Months of Age
    • 50
    Combination vaccines for childhood immunization.
    • 15
    • PDF
    Mumps and rubella eliminated from Finland.
    • 127
    Evaluation of Live Attenuated Varicella Vaccine (Oka‐RIT Strain) and Combined Varicella and MMR Vaccination in 13–17‐Month‐Old Children
    • 24
    Measles elimination in the Americas. Evolving strategies.
    • 254
    Interruption of measles transmission in Gipuzkoa (Basque Country), Spain.
    • 3
    Consensus: Varicella Vaccination of Healthy Children: A Challenge for Europe
    • 91